CliffBio
small molecule

DOXIL (LIPOSOMAL)

DOXORUBICIN HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyBaxter Healthcare Corp →See this company's full patent-cliff portfolio

Drug detail

Brand nameDOXIL (LIPOSOMAL)
Active ingredientDOXORUBICIN HYDROCHLORIDE
Strength20MG/10ML (2MG/ML)
Dosage formINJECTABLE, LIPOSOMAL
RouteINJECTION
ModalitySmall molecule
FDA approvalNovember 1995
Marketing statusRX

More from Baxter Healthcare Corp

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.